Latest news
Scholar Rock drops Novo manufacturing site from SMA drug application - Endpoints NewsEndpoints News · Mon, 10 Aug 2026 17:08:00 GMTScholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - BenzingaBenzinga · Mon, 10 Aug 2026 16:03:50 GMTScholar Rock's (SRRK) Outperform Rating Reiterated at Wedbush - MarketBeatMarketBeat · Mon, 10 Aug 2026 14:52:04 GMTScholar Rock Holding (SRRK) Advances Apitegromab Review, Is 11% Undervalued Enough? - simplywall.stsimplywall.st · Mon, 10 Aug 2026 14:38:10 GMTNovo’s Catalent plant ditched in FDA refiling of SMA drug - Fierce PharmaFierce Pharma · Mon, 10 Aug 2026 14:06:15 GMTA Quick Look at Today's Ratings for Scholar Rock(SRRK.US), With a Forecast Between $55 to $76 - MoomooMoomoo · Sat, 08 Aug 2026 01:36:29 GMTScholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 21:29:19 GMTScholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 20:20:00 GMT